Replies to post #66863 on Biotech Values

[masterlongevity]

i think erbitux is a stellar drug. why would you state otherwise?

[DewDiligence]

>anyone have any thoughts on whether Bristol will sweeten its offer?<

IMCL agreed to a “no shop” clause as part of the deal with LLY. Thus, the only way BMY or another company can beat LLY’s offer is to go hostile and launch a tender offer for more than $70/sh.